Author/Authors :
Amani Jafar نويسنده , Ranjbar Reza نويسنده , Mansouri Shahla نويسنده , Abdollahi Abbas نويسنده Department of Microbiology, Fasa University of Medical Sciences, Fars, Iran Abdollahi Abbas , Moradi Mohammad نويسنده , Ghasemi Amir نويسنده Associate Professor, Operative Dentistry, School of Dentistry, Shahid Behesht University of Medical Science. Shahid Behesht, Iran , Fasihi-Ramandi Mahdi نويسنده Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran Fasihi-Ramandi Mahdi
Abstract :
[Background]Brucellosis is one of the main causes of economic loss in domestic animals due to abortions and infertility. Brucella is a facultative intracellular pathogen that survives in other cell types in addition to phagocytes. T cell mediated responses are necessary to eradicate the infection due to Brucella.[Objectives]In this study the potential of recombinant protein rTF/Bp26/Omp31 as a novel Brucella subunit vaccine, protective efficacy, and immune response was evaluated in BALB/c mice.[Methods]After in silico design of rTF/Bp26/Omp31 structure, the gene was cloned and expressed in Escherichia coli BL21 (DE3). Finally, purified protein by Ni-NTA was used as immunogenic to immunized mice. [Results]Mice immunized with rTF/Bp26/Omp31 showed a vigorous humoral and cellular mediated immunity; results were compatible with IgG1 and IgG2a levels as well as high amounts of IFN-γ, IL-12, IL-4 and IL-10 production in immunized mice, compared with control groups (P < 0.05). Compared to control groups, mice vaccinated with rTF/Bp26/Omp31 showed a significant response and protection against subsequent Brucella infection (P < 0.05).[Conclusions]Statistical analyses indicate similar responses in immunized mice exposed to rTF/Bp26/Omp31, compared with B. abortus RB51 and B. melitensis Rev.1 vaccines. These results showed the potential of rTF/Bp26/Omp31 as a candidate for the development of a subunit vaccine against brucellosis.
